William Blair Investment Management LLC Purchases New Stake in Twist Bioscience Corporation $TWST

William Blair Investment Management LLC purchased a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,174,594 shares of the company’s stock, valued at approximately $223,722,000. Twist Bioscience makes up approximately 0.7% of William Blair Investment Management LLC’s holdings, making the stock its 29th largest holding.

Several other institutional investors also recently bought and sold shares of TWST. Quarry LP acquired a new stake in shares of Twist Bioscience in the third quarter worth $28,000. Western Wealth Management LLC acquired a new position in shares of Twist Bioscience during the 1st quarter valued at $31,000. Strs Ohio purchased a new stake in Twist Bioscience during the 1st quarter worth $33,000. Strategic Advocates LLC boosted its position in Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after purchasing an additional 906 shares during the period. Finally, SBI Securities Co. Ltd. increased its holdings in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares in the last quarter.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 113,318 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $125.16, for a total transaction of $14,182,880.88. Following the completion of the transaction, the chief executive officer directly owned 818,938 shares in the company, valued at approximately $102,498,280.08. This represents a 12.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the sale, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at $10,402,335.08. The trade was a 2.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 151,529 shares of company stock valued at $17,708,772 over the last 90 days. 3.08% of the stock is owned by company insiders.

Twist Bioscience Stock Up 6.8%

Shares of Twist Bioscience stock opened at $145.59 on Friday. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $145.93. The company has a market capitalization of $9.13 billion, a PE ratio of -65.58 and a beta of 2.14. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The business has a 50-day moving average of $100.69 and a 200-day moving average of $70.33.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.33 EPS. As a group, equities analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on TWST. Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective on the stock. in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Piper Sandler increased their target price on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Finally, Canaccord Genuity Group boosted their price target on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $98.30.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.